At AACR Annual Meeting 2026, investigators presented updated cohort results from the INFINITY phase 2 trial evaluating tremelimumab plus durvalumab as an organ-preserving option for resectable MSI-high, mismatch repair-deficient, and EBV-negative gastric and gastroesophageal junction cancer. In cohort two (18 patients), three patients experienced grade 3 immune-related adverse events, with no grade 4 or 5 events and no discontinuations. Two years after treatment, all 17 evaluable patients were alive, with a 71% clinical complete response rate and a 94.1% progression-free survival rate. Gastrectomy-free survival was 70.6% at two years. Exploratory ctDNA analyses showed baseline positivity in 13 of 17 evaluable patients and clearance in 11 of those 13 after treatment, aligning with the deep response signal reported across the cohort.